Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VYGR
VOYAGER THERAPEUTICS, INC.
NASDAQ
$3.54
▲ UP 2.31% (0.08)

KEY STATISTICS

Market Cap$213.89 M
52w High$5.55
52w Low$2.94
Dividend Yield—
Frequency—
P/E-1.97
Volume406.05K
Shares Out.60.42M

COMPANY

LEADERSHIP

Alfred W. Sandrock Jr.
CHIEF EXECUTIVE
Alfred W. Sandrock Jr.

COMPENSATION 2026

Salary$674,903
Stock Awards$611,900
Incentive Plan Pay$361,917
All Other Comp.$15,750
Total$2,508,370

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 11, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
141

PRICE TARGET

Target High$18.00
Target Low$8.00
Target Median$18.00
Target Consensus$14.40

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$6.35M
NOV
9
MON

PRICE

$3.54 ▲ UP 2.31% (+$0.08)
$3.38$3.45$3.539:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.54

About Voyager Therapeutics, Inc.

https://www.voyagertherapeutics.com ↗

Voyager Therapeutics, Inc. is a Cambridge-based gene therapy company developing treatments like VY-AADC for Parkinson's and preclinical programs for ALS, Huntington's, Friedreich's ataxia, tauopathies, and spinal muscular atrophy, with collaborati...

INDUSTRY

Biotechnology

A PRODUCT VOYAGER THERAPEUTICS, INC. IS KNOWN FOR

VY7523
VY7523

Voyager's most advanced wholly-owned anti-tau antibody, in clinical development for Alzheimer's disease, is currently in a multiple ascending dose study and is the company's leading therapeutic candidate.

COMPETITORS

COMPETITOR
ALEC COMPARE
DNLI COMPARE
QURE COMPARE
RGNX COMPARE
SG SGMO COMPARE

Revenue by Products

IconPRODUCTFY2017
Parkinsonprogram$5.5M

ETFS HOLDING THIS STOCK

ETFS HOLDING
73
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.7M
IWM
0.01% · 1.4M
FESM
0.01% · 158.6K
R2US.L
0.01% · 142.2K
AVSC
0.01% · 120.0K
GSSC
0.03% · 89.6K
DFAS
0.00% · 84.1K
PRFZ
0.01% · 83.9K
XRSU.L
0.01% · 48.1K
RSSL
0.01% · 24.9K
RFLR
0.06% · 16.9K
MNTL
0.43% · 15.0K
BIB
0.01% · 2.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
61.44%
HOLDERS
180
TOP 12 OF 180 · RANKED BY POSITION SIZE
Blackrock, Inc.
5.6M sh · $22.08M
Blackrock Inc.
5.3M sh · $42.02M
Armistice Capital, LLC
4.8M sh · $14.93M
Ecor1 Capital, LLC
4.0M sh · $15.73M
Millennium Management LLC
3.4M sh · $13.23M
Vanguard Group Inc
3.3M sh · $12.84M
Vestal Point Capital, LP
3.0M sh · $11.59M
Bb Biotech AG
2.9M sh · $54.85M
Dimensional Fund Advisors LP
1.3M sh · $5.99M
Opaleye Management Inc.
1.2M sh · $4.7M
Erste Asset Management Gmbh
1.2M sh · $4.72M
Geode Capital Management, LLC
1.1M sh · $5.36M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
SCANGOS GEORGE A
Purchase · 30.0K shares
2026-06-09
★
DIRECTOR
MACKEY CATHERINE J
Purchase · 30.0K shares
2026-06-09
★
DIRECTOR
Hyman Steven
Purchase · 30.0K shares
2026-06-09
★
DIRECTOR
Vitale Nancy
Purchase · 30.0K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ACHV$8.10COMPARE
ALLO$2.02COMPARE
ARCT$15.19COMPARE
AVIR$5.36COMPARE
ENTA$13.60COMPARE
SGMT$10.55COMPARE
VNDA$5.29COMPARE
TRDA$7.00COMPARE